Clinical trial data of Anti-PD-1/PD-L1 therapy for recurrent or metastatic nasopharyngeal Carcinoma: A review

Article Oncology

RATIONALE-309: Updated progression-free survival (PFS), PFS after next line of treatment, and overall survival from a phase 3 double-blind trial of tislelizumab versus placebo, plus chemotherapy, as first-line treatment for recurrent/metastatic nasopharyngeal cancer.

Li Zhang et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

P. Bossi et al.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Oncology

Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)

Feng-Hua Wang et al.

Summary: The study evaluated the antitumor activity and safety of toripalimab in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) refractory to standard chemotherapy, demonstrating a manageable safety profile and durable clinical response. Early decrease in plasma EBV DNA copy number was correlated with favorable response, indicating potential as a biomarker for treatment efficacy.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Review Oncology

Targeting the PD-1/PD-L1 interaction in nasopharyngeal carcinoma

David Johnson et al.

Summary: The upregulation of the PD-1/PD-L1 pathway is a possible immune-evasion mechanism in Epstein-Barr virus-associated nasopharyngeal cancer (NPC). Therapeutic targeting of this pathway is actively researched in NPC, with multiple monoclonal antibodies currently under evaluation in clinical settings. Combinatorial strategies involving cytotoxic chemotherapy, radiotherapy, and other immunotherapeutic agents are also being explored in clinical trials for NPC.

ORAL ONCOLOGY (2021)

Add to Collection

Meeting Abstract Oncology

Results of KEYNOTE-122: A phase III study of pembrolizumab (pembro) monotherapy vs chemotherapy (chemo) for platinum-pretreated, recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC)

A. T. Chan et al.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Oncology

Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer

Caroline Even et al.

Summary: The study found that spartalizumab had a shorter progression-free survival (PFS) compared to chemotherapy in patients with NPC, but longer overall survival and duration of response. The main adverse events associated with spartalizumab were fatigue and pruritus.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Oncology

Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study

Shaodong Hong et al.

Summary: The study found that among patients with previously untreated advanced nasopharyngeal carcinoma, those who received GP had longer overall survival compared to those who received FP. Gemcitabine plus cisplatin may be a preferred frontline option for these patients.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial

Hai-Qiang Mai et al.

Summary: The study is a double-blind phase 3 trial that shows the combination of toripalimab with GP chemotherapy for RM-NPC patients provides a superior PFS compared to GP alone. Most adverse events were similar between the two arms, but immune-related AEs were more frequent in the toripalimab arm.

NATURE MEDICINE (2021)

Add to Collection

Article Oncology